U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H9N2O3S.Na.H2O
Molecular Weight 254.239
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SULFACETAMIDE SODIUM

SMILES

O.[Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1

InChI

InChIKey=IHCDKJZZFOUARO-UHFFFAOYSA-M
InChI=1S/C8H10N2O3S.Na.H2O/c1-6(11)10-14(12,13)8-4-2-7(9)3-5-8;;/h2-5H,9H2,1H3,(H,10,11);;1H2/q;+1;/p-1

HIDE SMILES / InChI
Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C8H10N2O3S
Molecular Weight 214.242
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Sulfacetamide is a synthetic sulfonamide antibiotic, which exerts its effect through inhibition of bacterial dihydrofolate synthetase, an enzyme responsible for the conversion of p-aminobenzoic acid into folic acid in bacterias. The topical formulation of the drug is prescribed for the treatment of acne vulgaris and the ophtalmic formulation is used in patients with eye infections.

Approval Year

1941
157
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8583
BLEPHAMIDE

Approved Use

Blephamide ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies.

Launch Date

1961
Curative
Approved
8583
KLARON

Approved Use

Klaron Lotion is indicated in the topical treatment of acne vulgaris.

Launch Date

1996
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
99.2 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6663474/
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFACETAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1803 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6663474/
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFACETAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.3 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6663474/
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFACETAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
13 h
REVIEW
https://sci-hub.st/https://www.sciencedirect.com/science/article/pii/S0099542808606103
single, ocular
 SULFACETAMIDE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
82%
REVIEW
https://sci-hub.st/https://www.sciencedirect.com/science/article/pii/S0099542808606103
single, ocular
 SULFACETAMIDE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:63845
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63845
ChemicalBook
CB4264350
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4264350
eMolecules
511811
https://www.emolecules.com/cgi-bin/more?vid=511811
MolPort
MolPort-000-900-614
https://www.molport.com/shop/molecule-link/MolPort-000-900-614
ZINC
ZINC000005179119
http://zinc15.docking.org/substances/ZINC000005179119
PubMed

PubMed

TitleDatePubMed
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015-05-18
An alternative purification method for human serum paraoxonase 1 and its interactions with sulfonamides.
2010-12
Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial.
2010-11
[Rosacea: pathogenesis, clinical forms and therapy].
2010-07-25
Synthesis of novel selenium-containing sulfa drugs and their antibacterial activities.
2010-07-21
Curvularia keratomycosis in a dog.
2010-03
The multifunctionality of 10% sodium sulfacetamide, 5% sulfur emollient foam in the treatment of inflammatory facial dermatoses.
2010-03
Pharmacokinetic study on the mechanism of interaction of sulfacetamide sodium with bovine serum albumin: a spectroscopic method.
2010-03
Sulfacetamide loaded Eudragit® RL100 nanosuspension with potential for ocular delivery.
2010
Synthesis and biological activities of some novel triazoloquinazolines and triazinoquinazolines containing benzenesulfonamide moieties.
2010
A new and simple method to determine trace levels of sulfonamides in honey by high performance liquid chromatography with fluorescence detection.
2009-10-23
Updates on the pathophysiology and management of acne rosacea.
2009-09
Interaction of topical sulfacetamide and topical dapsone with benzoyl peroxide.
2009-09
Bioadhesive sulfacetamide sodium microspheres: evaluation of their effectiveness in the treatment of bacterial keratitis caused by Staphylococcus aureus and Pseudomonas aeruginosa in a rabbit model.
2009-08
Analytical method for simultaneous determination of pesticide and veterinary drug residues in milk by CE-MS.
2009-05
Treatment of papulopustular rosacea with sodium sulfacetamide 10%/sulfur 5% emollient foam.
2009-03
Rosacea and its topical management.
2009-02
Expression profile of CREB knockdown in myeloid leukemia cells.
2008-09-18
Comparative study of robustness between micellar electrokinetic capillary chromatography and high-performance liquid chromatography using one-variable-at-a-time and a new multi-variable-at-a-time approach.
2008-07-14
Ocular myasis and associated mucopurulent conjuctivitis acquired occupationally: A case study.
2008-04
Optimal conditions for determination of zinc bacitracin, polymyxin B, oxytetracycline and sulfacetamide in animal feed by micellar electrokinetic capillary chromatography.
2008-04
Application of liquid-liquid-liquid microextraction and high-performance liquid-chromatography for the determination of sulfonamides in water.
2008-03-31
Emerging topical antimicrobial options for mild-to-moderate acne: a review of the clinical evidence.
2008-02
N-(2,6-Dimethyl-phen-yl)-2-methyl-acetamide.
2008-01-09
Prescription refills and healthcare costs associated with topical metronidazole in Medicaid enrolled patients with rosacea.
2008
Researches concerning the synthesis and antituberculosis action of some new sulphacetamide derivatives.
2007-09-07
[Simultaneous determination of seven sulfonamides and metronidazole and chloramphenicol in cosmetics by high performance liquid chromatography].
2007-09
A sensitive spectrophotometric method for the determination of sulfonamides in pharmaceutical preparations.
2007-09
Pilot investigation of the hydrating effects of topical acne medications.
2007-08
Simultaneous determination of 17 sulfonamides and the potentiators ormetoprim and trimethoprim in salmon muscle by liquid chromatography with tandem mass spectrometry detection.
2007-03-22
Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy.
2007-03
[Determination of 12 sulfonamides in cosmetics by ultra performance liquid chromatography].
2007-03
Demodex folliculorum and Demodex brevis as a cause of chronic marginal blepharitis.
2007
Toxicity and biodegradability of sulfonamides and products of their photocatalytic degradation in aqueous solutions.
2006-11
Determination of sulfonamide antibiotics in wastewater: a comparison of solid phase microextraction and solid phase extraction methods.
2006-10-27
Combination topical therapy in the treatment of acne.
2006-08
Copper complexes with heterocyclic sulfonamides: synthesis, spectroscopic characterization, microbiological and SOD-like activities: crystal structure of [Cu(sulfisoxazole)2(H2O)4] . 2H2O.
2006-07
Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.
2006-04
Broad-specificity immunoassays for sulfonamide detection: immunochemical strategy for generic antibodies and competitors.
2006-03-01
Simultaneous determination of 16 sulfonamides in honey by liquid chromatography/tandem mass spectrometry.
2006-01-03
Topical therapies for rosacea.
2006-01
Monitoring of five sulfonamide antibacterial residues in milk by in-tube solid-phase microextraction coupled to high-performance liquid chromatography.
2005-11-02
Resistant scalp folliculitis secondary to Demodex infestation.
2005-11
Demodex mites as a cause of human disease.
2005-11
Refractory Demodex folliculitis in five children with acute lymphoblastic leukemia.
2005-09-30
Topical metronidazole combination therapy in the clinical management of rosacea.
2005-07-12
Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea.
2005-06
Multiresidue determination of sulfonamides in a variety of biological matrices by supported liquid membrane with high pressure liquid chromatography-electrospray mass spectrometry detection.
2004-09-08
Acute infectious conjunctivitis in childhood.
2001-07
Interaction of sulfonamide and sulfone compounds with Toxoplasma gondii dihydropteroate synthase.
1990-02
Patents

Patents

05908858
5
JP2006022101A
3

Sample Use Guides

In Vivo Use Guide
Topical: apply a thin film to affected areas twice daily. Ophtalmic suspension/ointment: two drops of suspension should be instilled into the conjunctival sac every four hours during the day and at bedtime. A small amount, approximately 1/2 inch ribbon of ointment, should be applied in the conjunctival sac three or four times daily and once or twice at night.
Route of Administration: Other
In Vitro Use Guide
P. aeruginosa, S. marcescens, St. epidermidis, C. albicans, and A. fumigatus (spores) were exposed to two ophthalmic solutions each formulated with 10% sodium sulfacetamide and a preservative. Sulfacetamide solutions preserved with thimerosal have MIC values ranging from 0.2 to 2.8 for the five test microorganisms. The solutions preserved with parabens exhibit slightly higher MIC values for Pseudomonas, Serratia, and spores of Aspergillus (1.5-6.5) and significantly higher MIC values for Staphylococcus and Candida (19.6 and 5.0, respectively).
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:47:31 GMT 2025
Edited
by admin
on Mon Mar 31 17:47:31 GMT 2025
Record UNII
4NRT660KJQ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BLEPHAMIDE COMPONENT SULFACETAMIDE SODIUM
Preferred Name English
SULFACETAMIDE SODIUM
EP   II   MART.   ORANGE BOOK   USP   USP-RS   VANDF   WHO-IP  
Common Name English
SODIUM SULFACETAMIDE
Common Name English
PREDSULFAIR COMPONENT SULFACETAMIDE SODIUM
Common Name English
SULFACETAMIDE SODIUM [ORANGE BOOK]
Common Name English
SULFACETAMIDE SODIUM [WHO-IP]
Common Name English
PREDAMIDE COMPONENT SULFACETAMIDE SODIUM
Common Name English
SULFACETAMIDE SODIUM [USP MONOGRAPH]
Common Name English
SULFACETAMIDE SODIUM [VANDF]
Common Name English
SULFACETAMIDE SODIUM [EP IMPURITY]
Common Name English
SULFACETAMIDE SODIUM [EP MONOGRAPH]
Common Name English
SULSTER COMPONENT SULFACETAMIDE SODIUM
Common Name English
SULFACEL
Brand Name English
SULPHRIN COMPONENT SULFACETAMIDE SODIUM
Common Name English
SODIUM N-SULFANILYLACETAMIDE MONOHYDRATE
Systematic Name English
NSC-625324
Code English
FML-S COMPONENT SULFACETAMIDE SODIUM
Common Name English
SODIUM SULAMYD
Brand Name English
SULFACETAMIDE SODIUM SALT MONOHYDRATE [MI]
Common Name English
METIMYD COMPONENT SULFACETAMIDE SODIUM
Common Name English
ACETAMIDE, N-((4-AMINOPHENYL)SULFONYL)-, MONOSODIUM SALT, MONOHYDRATE
Common Name English
SULFACETAMIDE SODIUM [MART.]
Common Name English
OCUSULF
Brand Name English
BLEPH
Brand Name English
CETAPRED COMPONENT SULFACETAMIDE SODIUM
Common Name English
KLARON
Brand Name English
SULFACETAMIDE SODIUM [USP-RS]
Common Name English
SULFACETAMIDUM NATRICUM [WHO-IP LATIN]
Common Name English
FLAMMAZINE
Common Name English
BLEPHAMIDE S.O.P. COMPONENT SULFACETAMIDE SODIUM
Common Name English
N-Sulfanilylacetamide monosodium salt monohydrate
Common Name English
SULFACETAMIDE SODIUM [II]
Common Name English
ISOPTO CETAPRED COMPONENT SULFACETAMIDE SODIUM
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29739
Created by admin on Mon Mar 31 17:47:31 GMT 2025 , Edited by admin on Mon Mar 31 17:47:31 GMT 2025
Code System Code Type Description
CAS
6209-17-2
Created by admin on Mon Mar 31 17:47:31 GMT 2025 , Edited by admin on Mon Mar 31 17:47:31 GMT 2025
PRIMARY
EVMPD
SUB04620MIG
Created by admin on Mon Mar 31 17:47:31 GMT 2025 , Edited by admin on Mon Mar 31 17:47:31 GMT 2025
PRIMARY
PUBCHEM
6419954
Created by admin on Mon Mar 31 17:47:31 GMT 2025 , Edited by admin on Mon Mar 31 17:47:31 GMT 2025
PRIMARY
EPA CompTox
DTXSID50211129
Created by admin on Mon Mar 31 17:47:31 GMT 2025 , Edited by admin on Mon Mar 31 17:47:31 GMT 2025
PRIMARY
FDA UNII
4NRT660KJQ
Created by admin on Mon Mar 31 17:47:31 GMT 2025 , Edited by admin on Mon Mar 31 17:47:31 GMT 2025
PRIMARY
ChEMBL
CHEMBL455
Created by admin on Mon Mar 31 17:47:31 GMT 2025 , Edited by admin on Mon Mar 31 17:47:31 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
SULFACETAMIDE SODIUM
Created by admin on Mon Mar 31 17:47:31 GMT 2025 , Edited by admin on Mon Mar 31 17:47:31 GMT 2025
PRIMARY Description: A white or yellowish white, crystalline powder; odourless. Solubility: Soluble in 1.5 parts of water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Antiinfective agent. Storage: Sulfacetamide sodium should be kept in a well-closed container, protected from light. Additional information: Even in the absence of light, Sulfacetamide sodium is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Definition: Sulfacetamide sodium contains not less than 99.0% and not more than 101.0% of C8H9N2NaO3S, calculated with reference to the anhydrous substance.
MERCK INDEX
m10301
Created by admin on Mon Mar 31 17:47:31 GMT 2025 , Edited by admin on Mon Mar 31 17:47:31 GMT 2025
PRIMARY
RS_ITEM_NUM
1624006
Created by admin on Mon Mar 31 17:47:31 GMT 2025 , Edited by admin on Mon Mar 31 17:47:31 GMT 2025
PRIMARY
NSC
625324
Created by admin on Mon Mar 31 17:47:31 GMT 2025 , Edited by admin on Mon Mar 31 17:47:31 GMT 2025
PRIMARY
CHEBI
9327
Created by admin on Mon Mar 31 17:47:31 GMT 2025 , Edited by admin on Mon Mar 31 17:47:31 GMT 2025
PRIMARY
DAILYMED
4NRT660KJQ
Created by admin on Mon Mar 31 17:47:31 GMT 2025 , Edited by admin on Mon Mar 31 17:47:31 GMT 2025
PRIMARY
RXCUI
82101
Created by admin on Mon Mar 31 17:47:31 GMT 2025 , Edited by admin on Mon Mar 31 17:47:31 GMT 2025
PRIMARY RxNorm
DRUG BANK
DBSALT000986
Created by admin on Mon Mar 31 17:47:31 GMT 2025 , Edited by admin on Mon Mar 31 17:47:31 GMT 2025
PRIMARY
CHEBI
63858
Created by admin on Mon Mar 31 17:47:31 GMT 2025 , Edited by admin on Mon Mar 31 17:47:31 GMT 2025
PRIMARY
NCI_THESAURUS
C29467
Created by admin on Mon Mar 31 17:47:31 GMT 2025 , Edited by admin on Mon Mar 31 17:47:31 GMT 2025
PRIMARY
Related Record Type Details
Structure of SULFACETAMIDE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of DAPSONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of SULFANILAMIDE
IMPURITY -> PARENT
correction factor: for the calculation of the content, multiply the peak area of impurity A by 0.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of N4-ACETYLSULFANILAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of N-((4-(ACETYLAMINO)PHENYL)SULFONYL)ACETAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of SULFACETAMIDE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966